[redacted]

FORM-39A

(THE DRUGS & COSMETICS ACT 1940 & RULES THEREUNDER)

C

Sample Name	AMLODIPINE BESILATE TABLETS-IP.2.5mg.	**Mfg Lic No**	[redacted]
Submitted By	Quality Control Advisor. (MMDSL) Shillong.	**Report No**	
Address	DHS LaitumkhrahNHM,EastKhasi Hills Meghalaya.	**Receipt Date**	19-Mar-24
Mfg By	N.S.	**Report Date**	01-Apr-24
Supplied By	N.S.	**Ref No**	N.S.

Batch No	Mfg. Date	Exp Date	Batch Size	Sample Qty
MMDSL/QC-0118	09/2023	08/2025	N.S.	60 TABS.

RESULT OF ANALYSIS

Date / Period of Performance of test 19/03/2024 to 01/04/2024.

Reference to protocol :- I.P-2022.

Description :- White round biconvex uncoated tablets.

Identification (by HPLC) :- Complies.

Related substances(by HPLC) :- Complies.

Average weight :- 198.7mg

Uniformity of Content (by HPLC) :- Within limits.

Dissolution (by U.V) :- Complies(88.26% to 94.43%) (Limit NLT 75%+5%)

Assay (by HPLC) :- Each uncoated tablet contains:-

Contents of	Obtd./Av.wt.	Claim	LIMIT Lower	Upper	Method
Amlodipine Besilate Cal. as Amlodipine	:- 2.48mg	2.5mg.	2.25mg.	2.75mg.	IP.

NOTE :- SAMPLE CONSUMED IN TESTING.

Report:In Opinion of the undersigned,The sample referred to above is of Standard Quality as defined in the Act and the rules made there under for the reason given: Complies as per IP.

[redacted]

NOTE : 1. The result listed refer only to the tested samples and applicable parameter. Endorsement of products is neither inferred nor implied.
2. Sample not drawn by us. Total liability of this laboratory limited to the invoice amount.
3. This report is not be reproduced wholly or in part and cannot be used as an evidence in the Court of Law and should not be used in any advertising media without special permission in writing.